| Stephanie H Lee, OD | |
|
220 N Mckemy Ave, Chandler, AZ 85226-2654 | |
| (480) 961-1865 | |
| Not Available |
| Full Name | Stephanie H Lee |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 220 N Mckemy Ave, Chandler, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205055662 | NPI | - | NPPES |
| 3747037 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1612 (Arizona) | Primary |
| 152W00000X | Optometrist | 12211T (California) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie H Lee, OD 220 N Mckemy Ave, Chandler, AZ 85226-2654 Ph: (480) 961-1865 | Stephanie H Lee, OD 220 N Mckemy Ave, Chandler, AZ 85226-2654 Ph: (480) 961-1865 |
News Archive
With $1.8 million in funding from the U.S. Centers for Disease Control and Prevention, the University of Illinois at Chicago will help young breast cancer survivors navigate post-treatment care and survival.
The International and American Associations for Dental Research (IADR/AADR) have published a paper titled "SSRIs and the Risk of Osseointegrated Implant Failure - A Cohort Study.
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2010 (3Q10) of $2.32, ahead of management's guidance of $1.65 to $1.75. The company earned $1.78 per share for the quarter ended September 30, 2009 (3Q09).
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
› Verified 7 days ago
Dr. David Christensen, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2050 N Alma School Rd, Chandler, AZ 85224 Phone: 480-786-1075 Fax: 480-786-0476 | |
James Sterenberg, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1717 W Chandler Blvd, Chandler, AZ 85224 Phone: 480-821-7565 | |
Dr. Nancy Nan-yin Liaw, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1815 E Queen Creek Rd, Ste. #2, Chandler, AZ 85286 Phone: 480-895-2020 Fax: 480-699-6724 | |
Vision Edge Eye Center Optometrist Medicare: Medicare Enrolled Practice Location: 7130 W Chandler Blvd Ste 19, Chandler, AZ 85226 Phone: 480-961-8999 Fax: 480-961-5009 | |
Kristin Renee Cerni, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 220 N Mckemy Ave, Chandler, AZ 85226 Phone: 480-518-1697 | |
Dr. Neal Weinstein, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 220 N Mckemy Ave, Chandler, AZ 85226 Phone: 480-961-1865 Fax: 480-961-4605 | |
Dr. David Palmieri, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 220 N Mckemy Ave, Chandler, AZ 85226 Phone: 480-961-1865 Fax: 480-961-1865 |